

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 October 2024 (03.10.2024)



(10) International Publication Number
WO 2024/206520 A1

(51) International Patent Classification:

C07D 281/02 (2006.01) *A61P 29/00* (2006.01)
A61P 25/22 (2006.01) *A61P 35/00* (2006.01)
A61P 25/24 (2006.01) *A61K 31/554* (2006.01)

(21) International Application Number:

PCT/US2024/021799

(22) International Filing Date:

27 March 2024 (27.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/454,958	27 March 2023 (27.03.2023)	US
63/463,299	01 May 2023 (01.05.2023)	US
63/466,999	16 May 2023 (16.05.2023)	US
63/468,221	22 May 2023 (22.05.2023)	US
63/528,631	24 July 2023 (24.07.2023)	US

(71) Applicants: **TONIX PHARMACEUTICALS**

HOLDING CORP. [US/US]; 26 Main Street, Suite 101,
Chatham, New Jersey 07928 (US). **TONIX PHARMA**
LIMITED [IE/IE]; 3 Marine Road, Dun Laoghaire, Dublin,
A96 HW25 (IE).

(72) Inventor; and

(71) Applicant: **LEDERMAN, Seth**; 124 Misham Point Road,
South Dartmouth, Massachusetts 02748 (US).

(72) Inventors: **DAUGHERTY, Bruce**; 82 Ironia Road, Mend-
ham, New Jersey 07945 (US). **FOGARTY, Siobhan J.**; 88
Temple Road, Blackrock, Dublin, A94 A2C3 (IE). **HAR-**
RIS, Herbert W.; 205 Westbury Drive, Chapel Hill, North
Carolina 27516 (US). **HSU, David Tai**; 4 Jacob Amsden
Road, Westborough, Massachusetts 01581 (US). **RIDE-**
OUT, Darryl C.; 158 Hawthorne Drive, Milford, Pennsyl-
vania 18337 (US). **SULLIVAN, Gregory M.**; 230 Mapes
Rd., Barryville, New York 12719 (US).

(74) Agent: **HALEY, James F.** et al.; **HALEY GUILIANO LLP**,
75 Broad Street, Suite 1000, New York, New York 10004
(US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: (S)-TIANEPTINE AND USE IN TREATING DISORDERS AND CONDITIONS ASSOCIATED WITH PEROXISOME
PROLIFERATOR-ACTIVATED RECEPTOR

(57) Abstract: The present disclosure provides the (S)-enantiomer of 7-(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodiben-
zo[c,f][1,2]thiazepin-11-ylamino)heptanoic acid ((S)-tianeptine) and the (S)-enantiomer of deuterated tianeptine (11-D-(S)-tianeptine),
both being characterized as comprising no more than 2%, or no more than about 0.1%, of the corresponding (R)-enantiomer. The present
disclosure further provides salts, amides, esters, co-crystals, crystals, analogs and pharmaceutical compositions thereof and methods of
using the (S)-enantiomers and those compounds and compositions for treating diseases, disorders or conditions of the CNS as well as
diseases, conditions and disorders associated with altered activity of, exacerbated by or modulated by the peroxisome proliferator-ac-
tivated receptors (PPAR)- β/δ and/or PPAR- γ , while minimizing or eliminating the potential for opioid abuse. The present disclosure
also provides methods of producing the (S)-enantiomer and 11-D-(S)-enantiomer and related compounds of this disclosure.

WO 2024/206520 A1